treatment emergent adverse events
- Business Wire
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is…
Read More » - Health
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Osaka, Japan: Study Results Showed Long-term Findings Consistent with the Known Safety Profile of TAKHZYRO with Reductions in the Rate…
Read More »